INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study enrolled 662 patients, both treatment-naïve and relapsed/refractory, and represents the first randomized head-to-head comparison of covalent and non-covalent BTK inhibitors.
Jaypirca met its primary endpoint of non-inferiority in overall response rate (ORR) compared to Imbruvica, achieving 87.0% ORR versus 78.5% in the intent-to-treat population. Results numerically favored Jaypirca across all patient groups, including those with high-risk features such as 17p deletions, IGHV status, and complex karyotype.
Progression-free survival (PFS), a key secondary endpoint, was not yet mature at the time of analysis but trended in favor of Jaypirca. In the treatment-naïve subgroup, which had the longest follow-up, Jaypirca demonstrated a 76% reduction in the risk of disease progression or death, highlighting its potential as an earlier-line therapy.
Safety outcomes were consistent with previous trials, with Jaypirca showing a favorable profile compared to Imbruvica. Rates of atrial fibrillation/flutter (2.4% vs. 13.5%) and hypertension (10.6% vs. 15.1%) were lower with Jaypirca, and fewer patients required dose reductions or discontinued treatment due to adverse events.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
